Chinook Therapeutics, Inc.
News
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Sees Significant Drop in Short Interest
Ticker Report Chinook Therapeutics, Inc. (NASDAQ:KDNY Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 2,880,000 shares, a drop of 13.5% from the July 15th total of 3,330,000 shares. Based on an average daily...\n more…
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Rating of "Hold" from Analysts
Ticker Report Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY Get Free Report) have earned an average rating of Hold from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating and three have ...\n more…
Novartis acquires Chinook Therapeutics for $3.5bn upfront
Pharmaceutical Business Review Stockholders of Chinook will receive $40.00 in cash per share, a total of $3.2bn, from Novartis. Upon achieving certain regulatory milestones, they will further receive $4.00 in cash\nThe post...\n more…
Chinook Therapeutics, Inc. Forecasted to Earn Q3 2023 Earnings of ($0.74) Per Share (NASDAQ:KDNY)
Zolmax Chinook Therapeutics, Inc. (NASDAQ:KDNY Free Report) Equities researchers at Wedbush raised their Q3 2023 earnings per share (EPS) estimates for shares of Chinook Therapeutics in a research report issued on Tuesday, August 8th. Wedbush analyst L. Chico now expects that the company will post earnings...\n more…
William Blair Analysts Lower Earnings Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY)
Zolmax Chinook Therapeutics, Inc. (NASDAQ:KDNY Free Report) Research analysts at William Blair lowered their Q2 2023 earnings estimates for Chinook Therapeutics in a research report issued to clients and investors on Tuesday, August 8th. William Blair analyst M. Phipps now anticipates that the company will...\n more…